SCHEMBL6691740

SCHEMBL6691740

COC(=O)COc1ccc(F)c2c1c1c(n2Cc2ccccc2)CCCC1C(N)=O.COc1ccc(F)c2c1c1c(n2Cc2ccccc2)CCCC1C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 13/20 0.44
TSPO P30536 2/20 0.39
PLA2G10 O15496 1/20 0.37
PLA2G1B P04054 1/20 0.37
PLA2G5 P39877 1/20 0.37
PLA2G2E Q9NZK7 1/20 0.37
HTR6 P50406 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8371555 0.98 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6691723 0.93 TSPO (0.44) PLA2G2ATSPOHTR6
SCHEMBL6696662 0.91 PLA2G2A (0.45) PLA2G2ATSPOPLA2G10PLA2G1BPLA2G5
SCHEMBL818609 0.90 PLA2G2A (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL29862385 0.90 PLA2G2A (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6693186 0.88 PLA2G2A (0.49) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL8371645 0.88 PLA2G2A (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6689087 0.86 TSPO (0.41) PLA2G2ATSPOHTR6
SCHEMBL27844993 0.84 FABP4 (0.37) TSPOHTR6
SCHEMBL6129588 0.83 FABP4 (0.36) PLA2G2ATSPOHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0950657-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors LILLY CO ELI (US) 2004-07-14 EP disclosed
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed
EP-0950657-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors ELI LILLY AND COMPANY (US) 1999-10-20 EP disclosed